

## **LIFECARE ASA: SHARE CAPITAL INCREASE AND WARRANTS REGISTERED**

Reference is made to the stock exchange announcement published by Lifecare ASA (the "Company") on 29 January 2026 regarding the board of directors' resolution to issue 12,000,000 new shares (the "Underwriting Commission Shares") to the underwriters of the partially underwritten rights issue of new shares in the Company (the "Rights Issue"), as settlement of their entitlement to underwriting commission.

The share capital increase pertaining to the issuance of 12,000,000 Underwriting Commission Shares has now been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 19,106,097.30 divided on 191,060,973 shares, each with a par value of NOK 0.10.

The underwriters of the Rights Issue were allocated warrants in two series: (a) three (3) warrants for every four (4) Underwriting Commission Shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 2 March 2026 to 13 March 2026 ("**Warrants Series 1**"); and (b) three (3) warrants for every four (4) Underwriting Commission Shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 1 June 2026 to 12 June 2026 ("**Warrants Series 2**" and together with Warrants Series 1, the "**Warrants**"). The issuance of the in total 18,000,000 Warrants allocated to underwriters of the Rights Issue (divided on 9,000,000 Warrants Series 1 and 9,000,000 Warrants Series 2) has now been registered with the Norwegian Register of Business Enterprises.

### **About us**

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

### **Contacts**

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42



**PRESS RELEASE**  
03 February 2026 09:02:00 CET

*This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-03 09:02 CET.*